Adagene Inc. 978.F Stock
Adagene Inc. Price Chart
Adagene Inc. 978.F Financial and Trading Overview
Adagene Inc. stock price | 2.3 EUR |
Previous Close | 1.08 EUR |
Open | 1.21 EUR |
Bid | 1.2 EUR x N/A |
Ask | 1.32 EUR x N/A |
Day's Range | 1.21 - 1.21 EUR |
52 Week Range | 0.89 - 6 EUR |
Volume | 220 EUR |
Avg. Volume | 0 EUR |
Market Cap | 57.58M EUR |
Beta (5Y Monthly) | 0.047155 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 33.89 EUR |
978.F Valuation Measures
Enterprise Value | -71078256 EUR |
Trailing P/E | N/A |
Forward P/E | -0.55760366 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 6.1967564 |
Price/Book (mrq) | 0.62597 |
Enterprise Value/Revenue | -7.649 |
Enterprise Value/EBITDA | 0.862 |
Trading Information
Adagene Inc. Stock Price History
Beta (5Y Monthly) | 0.047155 |
52-Week Change | -82.00000000000000000000000000000000% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6 EUR |
52 Week Low | 0.89 EUR |
50-Day Moving Average | 1.21 EUR |
200-Day Moving Average | 1.28 EUR |
978.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 43.77M |
Float | 16.55M |
Short Ratio | N/A |
% Held by Insiders | 10.67% |
% Held by Institutions | 9.71% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -903.078% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -30.68% |
Return on Equity (ttm) | -66.74% |
Income Statement
Revenue (ttm) | 9.29M EUR |
Revenue Per Share (ttm) | 0.22 EUR |
Quarterly Revenue Growth (yoy) | -39.10% |
Gross Profit (ttm) | N/A |
EBITDA | -82471152 EUR |
Net Income Avi to Common (ttm) | -79971848 EUR |
Diluted EPS (ttm) | -1.49 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 143.76M EUR |
Total Cash Per Share (mrq) | 3.34 EUR |
Total Debt (mrq) | 27.97M EUR |
Total Debt/Equity (mrq) | 33.66 EUR |
Current Ratio (mrq) | 2.711 |
Book Value Per Share (mrq) | 1.933 |
Cash Flow Statement
Operating Cash Flow (ttm) | -48611688 EUR |
Levered Free Cash Flow (ttm) | -19613868 EUR |
Profile of Adagene Inc.
Country | Germany |
State | N/A |
City | Suzhou |
Address | Building C14 |
ZIP | 215123 |
Phone | 86 512 8777 3632 |
Website | https://www.adagene.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 248 |
Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Q&A For Adagene Inc. Stock
What is a current 978.F stock price?
Adagene Inc. 978.F stock price today per share is 2.3 EUR.
How to purchase Adagene Inc. stock?
You can buy 978.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Adagene Inc.?
The stock symbol or ticker of Adagene Inc. is 978.F.
Which industry does the Adagene Inc. company belong to?
The Adagene Inc. industry is Biotechnology.
How many shares does Adagene Inc. have in circulation?
The max supply of Adagene Inc. shares is 47.14M.
What is Adagene Inc. Price to Earnings Ratio (PE Ratio)?
Adagene Inc. PE Ratio is now.
What was Adagene Inc. earnings per share over the trailing 12 months (TTM)?
Adagene Inc. EPS is -0.4 EUR over the trailing 12 months.
Which sector does the Adagene Inc. company belong to?
The Adagene Inc. sector is Healthcare.